ライフサイエンスコーパス: B-cell lymphoma

1 asia and, in some animals, mucosa-associated B cell lymphoma.

2 ly repair these off-target lesions can cause B cell lymphoma.

3 B cell function, induces the development of B cell lymphoma.

4 ve malignancy resembling human diffuse large B cell lymphoma.

5 clinically useful end point in diffuse large B-cell lymphoma.

6 ntreated elderly patients with diffuse large B-cell lymphoma.

7 eating patients with high-risk diffuse large B-cell lymphoma.

8 enesis in the c-Myc driven, Emu-Myc model of B-cell lymphoma.

9 Th2 ACT was also curative against B-cell lymphoma.

10 ffects in vivo in mouse models of Myc-driven B-cell lymphoma.

11 urkitt lymphoma and GC-derived diffuse large B-cell lymphoma.

12 cificity and cytotoxicity against A20 murine B-cell lymphoma.

13 ose with aggressive forms like diffuse large B-cell lymphoma.

14 form into germinal center-type diffuse large B-cell lymphoma.

15 l cancers, particularly multiple myeloma and B-cell lymphoma.

16 arge B-cell lymphoma and primary mediastinal B-cell lymphoma.

17 pic HCV strains derived from an HCV-positive B-cell lymphoma.

18 a, Hodgkin lymphoma, and primary mediastinal B-cell lymphoma.

19 mia, plasma cell neoplasms, or diffuse large B-cell lymphoma.

20 ooperate with Bcl2 overexpression to promote B-cell lymphoma.

21 with lymphoproliferative diseases, including B cell lymphomas.

22 evels and causes cell death in EBNA1-induced B cell lymphomas.

23 on and are associated with cancer, including B cell lymphomas.

24 human activated B cells and by several human B cell lymphomas.

25 ns with curative potential for patients with B-cell lymphomas.

26 e BCR expression is conserved in most mature B-cell lymphomas.

27 es using PDL immune-checkpoint inhibitors in B-cell lymphomas.

28 e biology and therapy of human marginal-zone B-cell lymphomas.

29 ently affected by chromosomal alterations in B-cell lymphomas.

30 in radiosensitive malignancies, particularly B-cell lymphomas.

31 ection is associated with increased risk for B-cell lymphomas.

32 ncluding mostly germinal center (GC)-derived B-cell lymphomas.

33 ome of high-risk patients with diffuse large B-cell lymphomas.

34 ntrolling acute infection and EBV-associated B-cell lymphomas.

35 se model strongly predisposed to spontaneous B-cell lymphomas.

36 Dynamic mathematical modeling and B cell lymphoma 2 (BCL2) overexpression revealed that te

37 ll survival via tissue-restricted control of B cell lymphoma 2 and IL-7Ralpha expression.

38 ia/lymphoma-2 associated X protein alpha and B cell lymphoma 2.

39 We found that the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (ABT-199)

40 proapoptotic and prosurvival members of the B-cell lymphoma 2 (Bcl-2) protein family.

41 molecules Sox2 and Nanog and anti-apoptotic B-cell lymphoma 2 (Bcl-2), respectively.

42 samples suggested the antiapoptotic mediator B-cell lymphoma 2 (BCL2) as a potential therapeutic targ

43 be largely rescued by ectopic expression of B-cell lymphoma 2 (Bcl2), despite a persisting block at

44 es involved in the control of cell survival (B-cell lymphoma 2 [BCL2]), cell proliferation (hepatocyt

45 d elevated levels of Mcl-1, an antiapoptotic B-cell lymphoma 2 family member, with selective reductio

46 The recently discovered role of the BCL2 (B-cell lymphoma 2 gene) promoter i-motif DNA in modulati

47 inhibitors of B-cell receptor signaling and B-cell lymphoma 2 have opened up new opportunities in th

48 further clarify the role of the proapoptotic B-cell lymphoma 2 homology domain 3 (BH3)-only protein B

49 The Bcl-2 (B-cell lymphoma 2) protein Bax (Bcl-2 associated X, apop

50 pression of downstream genes, such as Bcl-2 (B-cell lymphoma 2), c-Myc, MMP7 (matrix metalloproteinas

51 uch as nuclear factor kappa B, EGF, Wnt, and B-cell lymphoma 2.

52 The B-cell lymphoma-2 (Bcl-2) family proteins are critical r

53 um of pro- and anti-apoptotic members of the B-cell lymphoma-2 (Bcl-2) protein family in the mitochon

54 Inducible nitric oxide synthase (iNOS) and B-cell lymphoma-2-associated X (bax) protein expressions

55 re noncutaneous lymphomas were diffuse large B-cell lymphomas (32.4%), follicular lymphomas (15.3%),

56 urred in 6 of 14 patients with diffuse large B-cell lymphoma (43%; 95% CI, 18 to 71) and 10 of 14 pat

57 ation lead to constitutive expression of the B cell lymphoma 6 (BCL6) oncogene.

58 (+) T cells were capable of expressing PD-1, B cell lymphoma 6, and CXCR5 during early infection, ind

59 Inhibition of CD45 prevented expression of B-cell lymphoma 6 (Bcl-6), a transcriptional inhibitor t

60 itch of RNA processing, resulting in loss of B-cell lymphoma 6 (Bcl6) expression and increased Ig pro

61 ession of interferon regulatory factor 4 and B-cell lymphoma 6 (BCL6) in human peripheral blood monon

62 We show that Flt3 is reexpressed on B-cell lymphoma 6(+) germinal center B cells in vivo and

63 ng that of the GCB "master regulator," BCL6 (B-cell lymphoma 6).

64 B-cell lymphoma 6, IL-21, inducible costimulator, CXCR5,

65 B cell lymphoma-6 (Bcl-6) is a transcriptional repressor

66 atients (18 to 80 years old) with aggressive B-cell lymphomas (80% DLBCL) treated with rituximab and

67 ractions, bromodomains, and the beta-catenin/B-cell lymphoma 9 (BCL9) interaction were used to examin

68 lecule inhibitors selective for beta-catenin/B-cell lymphoma 9 (BCL9) over beta-catenin/cadherin PPIs

69 Three patients with diffuse large B-cell lymphoma achieved durable objective responses (tw

70 d efficacy in patients with refractory large B-cell lymphoma after the failure of conventional therap

71 ly, BCL-W was overexpressed in diffuse large B cell lymphoma and correlated with decreased patient su

72 B cell lymphoma and melanoma harbor recurrent mutations

73 , 29% of activated B-cell type diffuse large B-cell lymphoma and 90% of Waldenstrom macroglobulinemia

74 icular lymphoma and aggressive diffuse large B-cell lymphoma and are associated with H3K27me3 hyperac

75 cytolytic immune functions in patients with B-cell lymphoma and favorable clinical outcome.

76 estigated the effects of HDACi in Myc-driven B-cell lymphoma and five other hematopoietic malignancie

77 ment of relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

78 aB subunit c-Rel, is frequently amplified in B-cell lymphoma and functions as a tumour-promoting tran

79 tes to the immune control of CD27-expressing B-cell lymphoma and leukemia.

80 Diffuse large B-cell lymphoma and MCL had a poor prognosis, with 5-yea

81 radiotherapy in patients with diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma.

82 raffin-embedded tissues derived from primary B-cell lymphomas and 1 cell line to detect and character

83 binutuzumab, or ofatumumab) for treatment of B-cell lymphomas and chronic lymphocytic leukemia (CLL).

84 effects of BCR ablation on MYC-driven mouse B-cell lymphomas and compare them with observations in h

85 t translocations is also observed in various B-cell lymphomas and even some solid tumors.

86 reveal that BCL-W profoundly contributes to B cell lymphoma, and its expression could serve as a bio

87 lec) that is highly expressed on B-cells and B cell lymphomas, and is a validated target for antibody

88 expression was observed in HL, diffuse large B-cell lymphoma, and lymphoblastoid cell lines.

89 gnature in the ABC subgroup of diffuse large B-cell lymphoma, and one of the most frequent mutations

90 , I review the history of targeting BCL-2 in B-cell lymphomas, and I discuss recent data on venetocla

91 The molecular events that lead to B cell lymphoma are only partially defined.

92 ar lymphoma, and MYC/BCL2/BCL6 in high-grade B-cell lymphomas are essential for diagnosis.

93 9 in B-cell cancers, although data regarding B-cell lymphomas are limited.

94 Diffuse large B-cell lymphoma arising in immune-privileged sites (eg,

95 ll receptor (BCR) signaling in diffuse large B-cell lymphoma as a model system to establish a computa

96 Remarkably, diffuse large B cell lymphoma-associated gain-of-function mutations in

97 In germinal center diffuse large B-cell lymphoma, BCL-2 levels or venetoclax sensitivity

98 LF(-/-) p53(-/-) mice develop aggressive pro-B cell lymphomas bearing complex chromosomal translocati

99 n older patients with advanced diffuse large B-cell lymphoma, but further comparative studies are nee

100 n older patients with advanced diffuse large B-cell lymphoma, but further comparative studies are nee

101 cooperates with BCL6 in a mouse model of GC B-cell lymphoma, but not with the development of multipl

102 acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and respons

103 Here we report that the Casitas B-cell lymphoma (CBL) family E3 ubiquitin ligases down-r

104 Casitas B-cell lymphoma (Cbl) family ubiquitin ligases negativel

105 its the proliferation of human diffuse large B cell lymphoma cells that depend upon aberrant CARD11 s

106 that the expression of wild-type Galpha13 in B-cell lymphoma cells with mutant GNA13 has limited impa

107 ll-cycle arrest and apoptosis in Myc-induced B-cell lymphoma cells.

108 ternalized via hCD22 resulting in killing of B-cell lymphoma cells.

109 Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by poor clinical outcome.

110 Seven patients (0.48%) presented mature B-cell lymphoma consisting of 6 DLBCL and 1 FL.

111 Non-Hodgkin B-cell lymphomas constituted 83% (n = 71) and T-cell lym

112 uced to express an oncogenic form of diffuse B cell lymphoma (Dbl).

113 We carried out a proteomic analysis of a B cell lymphoma-derived cell line, BJAB, that requires U

114 ed by mutations in JAK2, CALR, or MPL In the B-cell lymphomas, detection of characteristic rearrangem

115 , Bcl-w loss profoundly delayed MYC-mediated B cell lymphoma development due to increased MYC-induced

116 B cell hyperactivity with increased risk for B cell lymphoma development.

117 B-cell activation seemed to play a role in B-cell lymphoma development at early stages across diffe

118 nated two prediagnostic blood samples before B-cell lymphoma diagnosis, along with 170 matched cancer

119 hat are frequently observed in diffuse large B cell lymphoma (DLBCL) and that disrupt ID-mediated aut

120 d EZH2 cooperate to accelerate diffuse large B cell lymphoma (DLBCL) development and combinatorial ta

121 plastic cells in patients with diffuse large B cell lymphoma (DLBCL) directly correlated with activat

122 Diffuse large B cell lymphoma (DLBCL) is the most common form of blood

123 onally developed therapies for diffuse large B cell lymphoma (DLBCL) requires rapid assimilation of n

124 d B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), engages the CARD11-MALT1-BCL10

125 r (GC) B cell-like subtypes of diffuse large B cell lymphoma (DLBCL).

126 th that in the closely related diffuse large B cell lymphoma (DLBCL).

127 ients have heightened risk for diffuse large B cell lymphoma (DLBCL).

128 ve genetic characterization of diffuse large B cell lymphomas (DLBCL), including large-scale exome ca

129 lymphoma (FL) (23% [n = 20]), diffuse large B-cell lymphoma (DLBCL) (10% [n = 9]), mantle cell lymph

130 (MCL) (6.8% [18 of 263]), and diffuse large B-cell lymphoma (DLBCL) (4.6% [12 of 263).

131 ients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged disease-free s

132 TORC pathway is upregulated in diffuse large B-cell lymphoma (DLBCL) and can be targeted with the mTO

133 hogenesis and heterogeneity of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) has

134 zed incidence ratios (SIRs) of diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) wer

135 mphomas (DELs) are subtypes of diffuse large B-cell lymphoma (DLBCL) associated with poor outcomes af

136 ockdown showed that almost all diffuse large B-cell lymphoma (DLBCL) cell lines are addicted to the e

137 or (ATF) family in survival of diffuse large B-cell lymphoma (DLBCL) cells.

138 Distinct subgroups of diffuse large B-cell lymphoma (DLBCL) genetically resemble specific ma

139 Diffuse large B-cell lymphoma (DLBCL) has been categorized into two mo

140 the development of BCL6-driven diffuse large B-cell lymphoma (DLBCL) in a murine model.

141 eral outlook for patients with diffuse large B-cell lymphoma (DLBCL) in first remission is important

142 Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease defin

143 ard treatment of patients with diffuse large B-cell lymphoma (DLBCL) is rituximab in combination with

144 Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in a

145 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of no

146 Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of no

147 Patients with relapsed diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem

148 A hallmark of the diffuse large B-cell lymphoma (DLBCL) of the activated B-cell (ABC) ty

149 Primary diffuse large B-cell lymphoma (DLBCL) of the ocular region is rare, an

150 , transformation to aggressive diffuse large B-cell lymphoma (DLBCL) reduces median survival to only

151 chemotherapy in limited-stage diffuse large B-cell lymphoma (DLBCL) remains controversial.

152 nd germinal center B-cell-like diffuse large B-cell lymphoma (DLBCL) represent the 2 major molecular

153 ressive activated B cell (ABC) diffuse large B-cell lymphoma (DLBCL) subtype from the better prognosi

154 The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in hist

155 Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) underwent both FLT and FDG PET/C

156 or patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncol

157 sion in human Burkitt (BL) and diffuse large B-cell lymphoma (DLBCL) xenografts blocked tumor growth,

158 euroblastoma, medulloblastoma, diffuse large B-cell lymphoma (DLBCL), and EOC microarray gene express

159 itt lymphoma, Hodgkin disease, diffuse large B-cell lymphoma (DLBCL), and posttransplant lymphoprolif

160 nd BCL2 genetic alterations in diffuse large B-cell lymphoma (DLBCL), apart from translocations, has

161 In diffuse large B-cell lymphoma (DLBCL), the number of circulating monoc

162 ell lymphoma gene-2 (BCL2), in diffuse large B-cell lymphoma (DLBCL).

163 rom diverse origins, including diffuse large B-cell lymphoma (DLBCL).

164 he inhibitor's cytotoxicity in diffuse large B-cell lymphoma (DLBCL).

165 inical trials of patients with diffuse large B-cell lymphoma (DLBCL).

166 f prognosis after treatment of diffuse large B-cell lymphoma (DLBCL).

167 s is increasingly impelling in diffuse large B-cell lymphoma (DLBCL).

168 of several neoplasms including diffuse large B-cell lymphoma (DLBCL).

169 B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL).

170 entified 2 major subclasses of diffuse large B-cell lymphoma (DLBCL).

171 a13, in Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL).

172 (FOXP1) is a common feature of diffuse large B-cell lymphoma (DLBCL).

173 cluding activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL).

174 homa (NLPHL) to transform into diffuse large B-cell lymphoma (DLBCL).

175 ssociated with poor outcome in diffuse large B-cell lymphoma (DLBCL).

176 l center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

177 CR) signaling in cell lines of diffuse large B-cell lymphoma (DLBCL).

178 of the role of this pathway in diffuse large B-cell lymphoma (DLBCL).

179 n follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL).

180 eatment of mutant MYD88(L265P) diffuse large B-cell lymphoma (DLBCL).

181 ly over-expressed in high-risk diffuse large B-cell lymphoma (DLBCL).

182 re on outcome in patients with diffuse large B-cell lymphoma (DLBCL).

183 licular lymphoma (FL; n = 29), diffuse large B-cell lymphoma (DLBCL; n = 34), DLBCL arising from chro

184 the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in thos

185 Diffuse large B cell lymphomas (DLBCLs) arise from proliferating B cel

186 nd will reclassify a subset of diffuse large B-cell lymphomas (DLBCLs) and HGBLs with features interm

187 Diffuse large B-cell lymphomas (DLBCLs) contain 2 major molecular subt

188 double- and triple-hit (DH/TH) diffuse large B-cell lymphomas (DLBCLs) feature activation of Hsp90 st

189 eceptor (BCR) signal-dependent diffuse large B-cell lymphomas (DLBCLs) inhibits cellular proliferatio

190 lase L1 (UCH-L1) is induced in diffuse large B-cell lymphomas (DLBCLs), and that levels of this molec

191 orted that early-stage gastric diffuse large B-cell lymphomas (DLBCLs), including DLBCLs with mucosa-

192 In diffuse large B-cell lymphomas (DLBCLs), JAK signaling is a feature of

193 sitive patients suffering from diffuse large B-cell lymphomas (DLBCLs).

194 Deep-sequencing analysis of B-cell lymphoma DNA confirmed that the telomerase revers

195 MCL, an uncommon B-cell lymphoma driven by dysregulated cyclin D1, respon

196 ht with relapsed or refractory diffuse large B-cell lymphoma (due to progressive disease in four pati

197 h 12.3% being misclassifications among small B-cell lymphoma entities.

198 an cooperate with human CD4 T cells to cause B cell lymphomas even when a major viral transforming pr

199 B-cell lymphomas express a functionally active and truly

200 We also identified B-cell lymphoma-extra large (Bcl-xL) as a key survival f

201 son-mediated gain-of-function alterations in B-cell lymphoma-extra large (Bcl-xL), Mdm4, and two TP53

202 olated transmembrane domains of Bax, Bcl-xL (B-cell lymphoma-extra large), and Bcl-2 can mediate inte

203 xygenase-1, inducible nitric oxide synthase, B-cell lymphoma-extra large, and protein expression of t

204 additional patients (two with diffuse large B-cell lymphoma, four with indolent lymphomas) had evide

205 alyses comparing senescent and non-senescent B-cell lymphomas from Emu-Myc transgenic mice revealed s

206 B-cell lymphomas from Mdm2(Tg);p73(+/-) mice retain the

207 he germinal center (GC) B-cell diffuse large B-cell lymphoma (GCB-DLBCL) subtype.

208 B cell lymphoma gene 2 (Bcl-2) family proteins are key r

209 cogenes, cellular-myelocytomatosis (MYC) and B-cell lymphoma gene-2 (BCL2), in diffuse large B-cell l

210 pression pattern of CD22 on B cells and most B cell lymphomas has made CD22 a therapeutic target for

211 inhibitors in the treatment of diffuse large B-cell lymphoma has not been defined; we suggest that JA

212 hich occur in <10% of cases of diffuse large B-cell lymphoma, have been referred to as double-hit lym

213 High-grade B-cell lymphomas (HGBLs) with MYC and BCL2 and/or BCL6 r

214 s, including Burkitt lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, and primary mediastin

215 hronic hepatitis C virus (HCV) infection and B-cell lymphoma, however, the mechanisms by which HCV ca

216 inib has demonstrated high response rates in B-cell lymphomas; however, a growing number of ibrutinib

217 be a crucial part of the pathophysiology of B-cell lymphomas; however, several early attempts to tar

218 urvival time for patients with diffuse large B-cell lymphoma, illustrate the behavior of our methodol

219 cking CD37 developed germinal center-derived B cell lymphoma in lymph nodes and spleens with a higher

220 owed that an LMP1-deleted EBV mutant induces B cell lymphomas in a newly developed cord blood-humaniz

221 Results for the treatment of B cell lymphomas in animal models and patient cells demo

222 n controlling the progression of early-stage B cell lymphomas in humans, we found higher expression o

223 arr virus (EBV) infection is associated with B cell lymphomas in humans.

224 y essential for the ability of EBV to induce B cell lymphomas in the cord blood-humanized mouse model

225 min under the control of CD19-Cre results in B-cell lymphomas in aging mice.

226 We consider B-cell lymphomas, including Burkitt lymphoma, diffuse la

227 aling pathways is a hallmark of a variety of B-cell lymphomas, including classical Hodgkin lymphoma (

228 mutated gene in germinal center (GC)-derived B-cell lymphomas, including nearly a quarter of Burkitt

229 The situation in diffuse large B-cell lymphoma is deceiving, as the possible gains of a

230 ine treatment in patients with diffuse large B-cell lymphomas is still a matter of debate.

231 that KLHL6, which is recurrently mutated in B cell lymphomas, is an off-target of the normal somatic

232 generated and characterized a panel of large B-cell lymphoma (LBCL) patient-derived xenograft (PDX) m

233 d Epstein-Barr virus-positive (EBV(+)) large B-cell lymphomas (LBCLs) in young patients without immun

234 icular lymphomas (PTLs) are extranodal large B-cell lymphomas (LBCLs) with inferior responses to curr

235 een characterized in primary cutaneous large B-cell lymphoma, leg type.

236 ins, with the founding member of the family (B-cell lymphoma/leukemia-2) discovered via its involveme

237 or end-stage renal disease, type 2 diabetes, B-cell lymphoma, lichen planus, Sjogren's syndrome, porp

238 use a targeted short-hairpin RNA screen in a B-cell lymphoma line to identify the BRCT-domain protein

239 CAR achieved sustained tumor regression in a B cell lymphoma model.

240 gnificantly reduced tumor burden in a murine B-cell lymphoma model.

241 nd in their human counterparts: IGK-CCND3 in B-cell lymphoma, MPB-BRAF in glioma, and COL3A1-PDGFB in

242 ents with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cel

243 amples, including FL (n = 20), diffuse large B-cell lymphoma (n = 10), classical Hodgkin lymphoma (n

244 cross NHL subtypes and 55% for diffuse large B-cell lymphoma (n = 11); median response duration was 4

245 (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10;

246 diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; per

247 lymphoma, Burkitt's lymphoma, diffuse large B-cell lymphomas, nasopharyngeal carcinoma (NPC), and ly

248 Severe infections and new-onset B-cell lymphoma occurred in 29.1% and 8.9% of cases, res

249 Extranodal marginal zone (MZ) B-cell lymphomas of the mucosa-associated lymphoid tissu

250 CTL019) to treat patients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed

251 Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractor

252 e large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma who

253 an indolent subtype to an aggressive form of B cell lymphoma over time (Richter s syndrome) and show

254 Lymphoma cells from diffuse large B-cell lymphoma patients had high basal phosphorylation

255 DS nor risk stratification of diffuse large B-cell lymphoma patients is affected by the choice of PE

256 O-based MDM4 targeting reduced diffuse large B cell lymphoma PDX growth.

257 f diffuse LBCL and primary mediastinal large B-cell lymphoma (PMBL).

258 significantly associated with diffuse large B cell lymphoma (pooled HR per SD: 1.47; 95% CI: 1.06, 2

259 2-3 or stage 3-4 CD20-positive diffuse large B-cell lymphoma, previously untreated, and not eligible

260 stleman's disease, as well as a rare form of B cell lymphoma (primary effusion lymphoma) primarily ob

261 we enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or

262 patients with newly diagnosed diffuse large B-cell lymphoma remains suboptimal in the rituximab era.

263 essment of IT-901 for the treatment of human B-cell lymphoma revealed antitumor properties in vitro a

264 ous NHL histologies, including diffuse large B-cell lymphoma, Richter's transformation, mantle cell l

265 homas, the association between diffuse large B-cell lymphoma risk and slope was restricted to CXCL13.

266 reactive B cells, and also have an increased B-cell lymphoma risk.

267 elapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL) are limited, and prognosis is

268 The adult high-grade B-cell lymphomas sharing molecular features with Burkitt

269 tivated B cell-like subtype of diffuse large B cell lymphoma somehow perturb ID-mediated autoinhibiti

270 ARD11 variants associated with diffuse large B cell lymphoma spontaneously induce Lin(Ub)n-Bcl10 prod

271 icular lymphoma misgrading and diffuse large B-cell lymphoma subtype misclassification.

272 study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma r

273 ory of lymphoma, separate from diffuse large B-cell lymphoma, termed high-grade B-cell lymphoma with

274 e outcome of ACT against a mouse non-Hodgkin B cell lymphoma that expresses OVA as a model neoantigen

275 MCL is an aggressive B-cell lymphoma that overexpresses cyclin D1 with relati

276 mpaired in approximately 6% of diffuse large B-cell lymphomas that carry inactivating genetic alterat

277 Given that p73 is lost or silenced in human B-cell lymphomas, the Mdm2(Tg);p73(+/-) mouse serves as

278 ranslocations associated with GC and post-GC B-cell lymphomas, the role of downstream AID-associated

279 et al used an immunocompetent mouse model of B-cell lymphoma to discover an interesting new way in wh

280 Nineteen patients had diffuse large B-cell lymphoma, two patients had follicular lymphoma, a

281 Current diagnostic tests for diffuse large B-cell lymphoma use the updated WHO criteria based on bi

282 and eight of 20 patients with diffuse large B-cell lymphoma vs one of 15 patients with follicular ly

283 f prostate cancer mortality or diffuse large B-cell lymphoma was limited.

284 A mouse model of human B-cell lymphoma was utilized to test in vivo efficacy of

285 ective study in patients with advanced-stage B-cell lymphoma, we investigated the prognostic and pred

286 eviously untreated DLBCL or other aggressive B-cell lymphoma were 60 to 80 years old, had CR or PR af

287 Overall, 126 patients with diffuse large B-cell lymphoma were included (56 female and 70 male; me

288 Patients with any stage of diffuse large B-cell lymphoma were treated with six cycles of R-CHOP-1

289 tory NHL, who included 14 with diffuse large B-cell lymphoma, were enrolled; 42 received treatment in

290 homa (NMZL) is a rare form of indolent small B-cell lymphoma which has only been clearly identified i

291 immunotherapy in patients with diffuse large B-cell lymphoma who are not candidates for transplantati

292 6 months, 86% of patients with diffuse large B-cell lymphoma who had a response (95% CI, 33 to 98) an

293 center study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi

294 ents with Hodgkin lymphoma and diffuse large B-cell lymphoma will relapse, requiring additional thera

295 Mantle-cell lymphoma is an aggressive B-cell lymphoma with a poor prognosis.

296 f adult Burkitt lymphoma (BL) and high-grade B-cell lymphoma with BL gene signature (adult-molecularl

297 diatric-type follicular lymphoma (PTFL) is a B-cell lymphoma with distinctive clinicopathological fea

298 use large B-cell lymphoma, termed high-grade B-cell lymphoma with translocations involving myc and bc

299 amplified in the FL context, unlike in other B-cell lymphomas with a follicular growth pattern.

300 lar lymphoma (PTL) are rare extranodal large B-cell lymphomas with similar genetic signatures.